Introduction. Up to 20% so-called secondary forms of hypertension are associated with vascular pathology of the kidneys (renovascular hypertension). The lack of effectiveness of drug therapy of this form of hypertension determined the invasive treatment tactics. Objectives. The purpose of this article was to observe the clinical course of renovascular hypertension and determine the tactics of treatment in the long-term period after a previous stenting of the renal arteries. Material and methods. Our patient is a woman, born in 1957. Since 2011, hypertension has been diagnosed, since 2014 - rhythm disturbances, since 2015 edema of the lower extremities, maximum blood pressure up to 250/120 mm Hg, in 2016 - stenting of the renal arteries (RA) was performed according to the angiography results, the patient's condition was satisfactory. Since 2018, due to deterioration, the patient was hospitalized. The main diagnosis: Secondary vasorenal arterial hypertension of the II stage, 3 degree. Bilateral renal artery stenosis (angiography 03.03.2016). Renal artery stenting (03.03.2016). Restenosis of the stent of the right renal artery up to 80% (angiography 15.11.2018). Ventricular extrasystole II gradation according to Laun-Wolf-Rayan. Hyperlipidemia type IIb-III. Very high cardiovascular risk. Complication: Hypertensive crisis (uncomplicated course) (01.1I.2018). HF II A stage, class II with preserved systolic function of the left ventricle (EF 69%). Conducted therapy: perindopril 15 mg, bisoprolol 5 mg, torasemide 5 mg; amiodarone 100 mg bid; indapamide 1.25 mg; amlodipine 5 mg, acetylsalicylic acid 150 mg; rosuvastatin 20 mg. Results. The patient underwent a standard examination at hospital. Identified deviations: laboratory: ESR 20 mm / h, basophils 1.3%, creatinine 83 μmol / L (CKD-EPI 77 ml / min / 1.73 m2), dyslipidemia IIb according to Fredrickson; instrumental: ECG – left axis deviation, signs of left ventricular myocardial hypertrophy (LVMH); Holter - single ventricular and supraventricular extrasystoles; echocardiography - sclerotic changes in the valvular apparatus of the heart, concentric LVMH; ultrasound of the abdominal cavity and retroperitoneal space – the right kidney is reduced in size, microcalculosis of both kidneys, signs of stenotic flow along the left RA at the level of the stent; RA angiography - restenosis in the stent of the right RA up to 80%. Stentoplasty with possible stent-to-stent DES stenting was recommended by an endovascular surgeon. Conclusions. This clinical case demonstrates the need for screening a category of patients with resistance to standard antihypertensive therapy for the presence of secondary arterial hypertension, which will improve the quality of life of the patient and reduce the number of drugs used, in some cases up to their withdrawal. Given the high likelihood of restenosis of stented vessels, it is necessary to carry out primary prevention of the restenosis occurrence.
On the example of the clinical case of newly diagnosed ST-elevation myocardial infarction combination of different reperfution strategies and their benefit was discussed. Recommendations on lifestyle modification and medicament treatment tactics are described. From one hand, in spite of side-effects of treatment as an increased risk of stroke and hemorrhagic stroke, prehospital FL is associated with a decreased risk of cardiogenic shock and its effectiveness depends on the time from symptom onset to reperfusion. From other hand, despite the fact that PPCI is the recommended default reperfusion strategy, its effectiveness depends also on time limits and absence of the majority of PPCI-facilated hospitals worldwide. Combination of prehospital single-bolus FL following after 3–24h early routine angiography and PCIcan improve post-STEMI survival and help to avoid hyperreactivity and thrombin-induced platelet activation after FL, which can be a key to success in effective treatment and rehabilitationafter STEMI in patients without high risk factors of potential bleeding or stroke.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.